Compare ANPA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | MPLT |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.9M | 772.7M |
| IPO Year | 2025 | 2025 |
| Metric | ANPA | MPLT |
|---|---|---|
| Price | $20.40 | $17.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 151.5K | ★ 202.1K |
| Earning Date | 03-13-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $6,249,472.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.20 | N/A |
| 52 Week Low | $2.80 | $12.24 |
| 52 Week High | $108.68 | $21.55 |
| Indicator | ANPA | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 49.23 |
| Support Level | $72.00 | $17.00 |
| Resistance Level | $81.00 | $18.91 |
| Average True Range (ATR) | 13.41 | 1.24 |
| MACD | -7.25 | -0.02 |
| Stochastic Oscillator | 3.46 | 51.88 |
Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.